Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients.
J Am Acad Dermatol
; 55(4): 590-7, 2006 Oct.
Article
en En
| MEDLINE
| ID: mdl-17010737
ABSTRACT
BACKGROUND:
Etanercept is a tumor necrosis factor-alpha binding fusion protein that demonstrates efficacy in the treatment of psoriasis, which is accompanied by decreased plaque infiltration of T cells and myeloid dendritic cells. We hypothesized that etanercept decreases inflammatory cell infiltration by inducing apoptosis.OBJECTIVE:
We sought to investigate the effect of etanercept on circulating and plaque leukocyte apoptosis in psoriasis.METHODS:
Blood and plaque specimens were obtained from 10 patients with psoriasis treated with etanercept (25 mg subcutaneously twice weekly) for 24 weeks. Apoptosis was determined in tissue samples using immunohistochemistry and flow cytometry.RESULTS:
Etanercept selectively induced apoptosis in dermal dendritic cells in plaques of responding patients at 1 month, before most of the clinical and histologic response was achieved. No apoptosis was detected in plaque or circulating T cells or in circulating monocytes.LIMITATIONS:
Addition of multiple time points earlier than 1 month would be valuable to establish the time point of maximum induction in cell apoptosis.CONCLUSION:
Etanercept selectively induces apoptosis of pathogenic dermal dendritic cells in responding patients early in the course of treatment.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Piel
/
Células Dendríticas
/
Inmunoglobulina G
/
Factor de Necrosis Tumoral alfa
/
Apoptosis
/
Receptores del Factor de Necrosis Tumoral
/
Leucocitos
Límite:
Adolescent
/
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Am Acad Dermatol
Año:
2006
Tipo del documento:
Article
País de afiliación:
Estados Unidos